Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
Brinkmann
Volker
V
Department of Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus Forum 1, WSJ-386, CH-4056 Basel, Switzerland. volker.brinkmann@novartis.com
Billich
Andreas
A
Baumruker
Thomas
T
Heining
Peter
P
Schmouder
Robert
R
Francis
Gordon
G
Aradhye
Shreeram
S
Burtin
Pascale
P
D000284:Administration, Oral; D000818:Animals; D055808:Drug Discovery / Q000639:trends*; D000068876:Fingolimod Hydrochloride; D006801:Humans; D018836:Inflammation Mediators / Q000008:administration & dosage; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000473:pathology; D011409:Propylene Glycols / Q000008:administration & dosage*; D012106:Research / Q000639:trends*; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D018836:Inflammation Mediators; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine